A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors Maxime Chénard-PoirierAaron R. HansenManish R. Sharma Research Open access 14 March 2024
Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status Aaron ShaykevichDanbee ChaeRadhashree Maitra Research Open access 06 March 2024 Pages: 229 - 239
A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer Andrew H. KoAndrew L. CovelerShih-Yao Lin Research 05 March 2024 Pages: 221 - 228
The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages Petra HenningAnna WesterlundUlf H. Lerner Research Open access 01 March 2024 Pages: 207 - 220
First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab? Yuanyuan ZhaoTing MeiYouling Gong Research Open access 22 February 2024 Pages: 196 - 206
Learn more about Springer Nature’s oncology titles Discover the range of academic oncology titles at Springer Nature here.